Daniel K. Treiber
Recludix Pharma (United States)(US)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Computational Drug Discovery Methods, RNA and protein synthesis mechanisms, Chronic Myeloid Leukemia Treatments, RNA modifications and cancer
Most-Cited Works
- → A quantitative analysis of kinase inhibitor selectivity(2008)2,427 cited
- → Comprehensive analysis of kinase inhibitor selectivity(2011)2,330 cited
- → A small molecule–kinase interaction map for clinical kinase inhibitors(2005)1,903 cited
- → Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases(2005)554 cited
- → Dual kinase-bromodomain inhibitors for rationally designed polypharmacology(2014)348 cited
- → Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680(2006)275 cited
- → Exposing the kinetic traps in RNA folding(1999)228 cited
- → Kinetic Intermediates Trapped by Native Interactions in RNA Folding(1998)213 cited
- → Beyond kinetic traps in RNA folding(2001)193 cited
- → Progress towards a public chemogenomic set for protein kinases and a call for contributions(2017)168 cited